Journal of Contemporary Brachytherapy
eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Share:
Send email
Share:
abstract:
Original paper

High-dose-rate brachytherapy for eyelid carcinoma: Implant technique and review

Jose Luis Guinot
1
,
Cristina Gutierrez
2
,
Mar Vercher
1
,
Marc Juárez
2
,
Miguel Angel Santos
1
,
Monica Núñez
1
,
Sandra Canos
1
,
Andrea Slocker
2
,
Dina Najjari
2

  1. Department of Radiation Oncology, Fundacion Instituto Valenciano de Oncologia (I.V.O.), Valencia, Spain
  2. Department of Radiation Oncology, Institut Català d’Oncologia (I.C.O.), L’ Hospitalet (Barcelona), Spain
J Contemp Brachytherapy 2025
DOI: https://doi.org/10.5114/jcb.2025.158163
Online publish date: 2025/12/21
View full text Get citation
 
Eyelid carcinoma is a tumor often detected at an early stage, which can be managed surgically. In non-surgical cases, brachytherapy is a valid alternative or as adjuvant therapy when risk factors exist. Basal cell carcinoma is the most common type of eyelid cancer, usually occurring in the lower eyelid. Interstitial technique with plastic tubes is a simple procedure in this location. High-dose rate (HDR) brachytherapy offers local control rates greater than 94%, with few side effects and good function preservation. This article provided practical description of the technique and review of literature. Collaboration between ophthalmology, dermatology, and brachytherapy specialists is essential to achieve the best patient outcomes.
keywords:

brachytherapy, technique, high-dose-rate, carcinomas, eyelid

  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.